Walter S. Kerr, Jr. Distinguished Professor of Surgery
Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, Bostwick DG
Predictors of cancer progression in T1a prostate adenocarcinoma. Cancer. 1999 Mar 15; 85(6):1300-4.
Predictors of cancer progression in T1a prostate adenocarcinoma.
Ghavamian R, Blute ML, Bergstralh EJ, Slezak J, Zincke H
Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Incidental discovery of pelvic leiomyosarcoma at radical prostatectomy. J Urol. 2000 Jun; 163(6):1866.
Incidental discovery of pelvic leiomyosarcoma at radical prostatectomy.
Karnes RJ, Gettman MT, Anderson PM, Lager DJ, Blute ML
Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus. J Urol. 2000 Sep; 164(3 Pt 1):772.
Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus.
Ackerman SJ, Rein AL, Blute M, Beusterien K, Sullivan EM, Tanio CP, Manyak MJ, Strauss MJ
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology. 2000 Dec 20; 56(6):972-80.
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods.
Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC, Partin AW
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001 Jun; 57(6):1033-7.
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.
Manyak MJ, Ackerman SJ, Blute ML, Rein AL, Buesterien K, Sullivan EM, Tanio CP, Strauss MJ
Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy. J Endourol. 2002 Feb; 16(1):51-6.
Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy.
Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN
Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 2001 Sep 01; 61(17):6494-9.
Role of HPC2/ELAC2 in hereditary prostate cancer.
Montgomery BT, Kelalis PP, Blute ML, Bergstralh EJ, Beckwith JB, Norkool P, Green DM, D'Angio GJ
Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study. J Urol. 1991 Aug; 146(2 ( Pt 2)):514-8.
Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study.
Surgical management of renal cell carcinoma invading the vena cava. Curr Urol Rep. 2002 Feb; 3(1):37-43.
Surgical management of renal cell carcinoma invading the vena cava.
Leibovich BC, Blute M, Cheville JC, Lohse CM, Weaver AL, Zincke H
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol. 2004 Mar; 171(3):1066-70.
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.
Blute ML, Patterson DE, Segura JW, Tomera KM, Hellerstein DK
Transurethral microwave thermotherapy v sham treatment: double-blind randomized study. J Endourol. 1996 Dec; 10(6):565-73.
Transurethral microwave thermotherapy v sham treatment: double-blind randomized study.
Amling CL, Blute ML, Bergstralh EJ, Slezak JM, Martin SK, Zincke H
Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):222-9.
Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Sakr WA, Wheeler TM, Blute M, Bodo M, Calle-Rodrigue R, Henson DE, Mostofi FK, Seiffert J, Wojno K, Zincke H
Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen. Cancer. 1996 Jul 15; 78(2):366-8.
Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen.
Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I
Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol. 2007 Feb; 177(2):477-80.
Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002 Dec; 168(6):2395-400.
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 01; 113(7):1544-51.
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
Radical prostatectomy: does surgical technique influence margin control? Urol Oncol. 2010 Mar-Apr; 28(2):219-25.
Radical prostatectomy: does surgical technique influence margin control?
Graff RE, Sanchez A, Tobias DK, Rodríguez D, Barrisford GW, Blute ML, Li Y, Sun Q, Preston MA, Wilson KM, Cho E
Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care. 2018 07; 41(7):1432-1437.
Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies.
Breau RH, Crispen PL, Jenkins SM, Blute ML, Leibovich BC
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol. 2011 Feb; 185(2):407-13.
Treatment of patients with small renal masses: a survey of the American Urological Association.
Humphreys MR, Gettman MT, Chow GK, Zincke H, Blute ML
Minimally invasive radical prostatectomy. Mayo Clin Proc. 2004 Sep; 79(9):1169-80.
Minimally invasive radical prostatectomy.
Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173(6):1893-6.
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.
Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009 May 15; 115(10):2092-103.
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.
Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE
Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009 Jun; 55(6):1251-65.
Pelvic lymph node dissection in prostate cancer.
Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7.
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Radical prostatectomy for high-risk prostate cancer. Jpn J Clin Oncol. 2010 Jan; 40(1):3-9.
Radical prostatectomy for high-risk prostate cancer.
Blute ML, Segura JW, Patterson DE, Benson RC, Zincke H
Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol. 1989 Jun; 141(6):1298-301.
Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer.
Lerner SE, Mann BS, Blute ML, Richardson RL, Zincke H
Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results. Mayo Clin Proc. 1995 Sep; 70(9):821-8.
Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results.
Renal tumors. J Urol. 1994 Jul; 152(1):43-4.
Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol. 1996 Mar; 155(3):821-6.
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR, Frank I, Permpongkosol S, Weight CJ, Kaouk JH, Kattan MW, Novick AC
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007 Jul; 178(1):41-6.
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors.
Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Elliott DS, Blute ML
Imperative indications for conservative management of upper tract transitional cell carcinoma. J Urol. 2007 Sep; 178(3 Pt 1):792-6; discussion 796-7.
Imperative indications for conservative management of upper tract transitional cell carcinoma.
Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol. 2006 Mar; 175(3 Pt 1):952-7.
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.
Thompson RH, Frank I, Lohse CM, Saad IR, Fergany A, Zincke H, Leibovich BC, Blute ML, Novick AC
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol. 2007 Feb; 177(2):471-6.
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study.
Strawbridge LR, Blute ML, James EM, Gillespie DJ
Intraoperative ultrasonographically guided biopsy in testicular sarcoidosis: a case report. J Urol. 1990 Jun; 143(6):1229-31.
Intraoperative ultrasonographically guided biopsy in testicular sarcoidosis: a case report.
Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML
Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008 Apr; 179(4):1349-52; discussion 1352-3.
Radical retropubic prostatectomy in immunosuppressed transplant recipients.
Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW
Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008 Jun; 179(6):2146-51; discussion 2151.
Preoperative nomogram predicting 12-year probability of metastatic renal cancer.
Kashanian J, Hakimian P, Blute M, Wong J, Khanna H, Wise G, Shabsigh R
Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int. 2008 Dec; 102(11):1634-7.
Nitrofurantoin: the return of an old friend in the wake of growing resistance.
Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009 Feb; 55(2):261-70.
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
Maximally Invasive Ablation Versus Minimally Invasive Partial Nephrectomy. Eur Urol Focus. 2015 Aug; 1(1):73-74.
Maximally Invasive Ablation Versus Minimally Invasive Partial Nephrectomy.
Gershman B, Psutka SP, McGovern FJ, Dahl DM, Tabatabaei S, Gettman MT, Frank I, Carlson RE, Rangel LJ, Barry MJ, Blute ML, Karnes RJ
Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals. Eur Urol Focus. 2016 Jun; 2(2):172-179.
Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals.
Thomas AZ, Blute ML, Seitz C, Habra MA, Karam JA
Management of the Incidental Adrenal Mass. Eur Urol Focus. 2016 Feb; 1(3):223-230.
Management of the Incidental Adrenal Mass.
Cross fused renal ectopia with associated renal cell carcinoma. Urol Case Rep. 2018 May; 18:70-72.
Cross fused renal ectopia with associated renal cell carcinoma.
Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED
Clinical cancer research : an official journal of the American Association for Cancer Research
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1915-23.
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
Use and timing of radiotherapy in high-risk prostate cancer. JAMA. 2004 Jun 16; 291(23):2817; author reply 2817-8.
Use and timing of radiotherapy in high-risk prostate cancer.
Dimarco DS, Lohse CM, Zincke H, Cheville JC, Blute ML
Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy. Urology. 2004 Sep; 64(3):462-7.
Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Critical comparison of laparoscopic, robotic, and open radical prostatectomy: techniques, outcomes, and cost. Curr Urol Rep. 2006 May; 7(3):193-9.
Critical comparison of laparoscopic, robotic, and open radical prostatectomy: techniques, outcomes, and cost.
Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006 Aug; 176(2):559-63.
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Atwell TD, Farrell MA, Callstrom MR, Charboneau JW, Leibovich BC, Patterson DE, Chow GK, Blute ML
Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience. Radiology. 2007 Apr; 243(1):276-83.
Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience.
Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res. 2007 Apr 01; 67(7):2944-50.
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML
Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H
Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J Urol. 1999 Oct; 162(4):1282-4; discussion 1284-5.
Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults.
Ghavamian R, Cheville JC, Lohse CM, Weaver AL, Zincke H, Blute ML
Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol. 2002 Aug; 168(2):454-9.
Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H
Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002 Aug; 168(2):525-9.
Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Long-term followup of young patients with stage A adenocarcinoma of the prostate. J Urol. 1986 Oct; 136(4):840-3.
Long-term followup of young patients with stage A adenocarcinoma of the prostate.
Archives of pathology & laboratory medicine
Multifocal malignant melanoma arising in vesicovaginal melanosis. Arch Pathol Lab Med. 1991 Sep; 115(9):950-2.
Multifocal malignant melanoma arising in vesicovaginal melanosis.
Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005 Mar; 173(3):918-21.
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, Blute ML, Zincke H
Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology. 2006 Sep; 68(3):604-8.
Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy.
Tollefson MK, Blute ML, Farmer SA, Frank I
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol. 2010 Jan; 183(1):81-6.
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma.
Crispen PL, Tabidian MR, Allmer C, Lohse CM, Breau RH, Blute ML, Cheville JC, Leibovich BC
Unclassified renal cell carcinoma: impact on survival following nephrectomy. Urology. 2010 Sep; 76(3):580-6.
Unclassified renal cell carcinoma: impact on survival following nephrectomy.
Blute ML, Kelalis PP, Offord KP, Breslow N, Beckwith JB, D'Angio GJ
Bilateral Wilms tumor. J Urol. 1987 Oct; 138(4 Pt 2):968-73.
Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 01; 13(7):2075-81.
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML
Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2008 Feb; 101(3):299-304.
Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Microwave thermotherapy for the treatment of benign prostatic hyperplasia. Semin Urol. 1994 Aug; 12(3):181-92.
Microwave thermotherapy for the treatment of benign prostatic hyperplasia.
Kletscher BA, Qian J, Bostwick DG, Blute ML, Zincke H
Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol. 1996 Jun; 155(6):1844-6.
Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma.
Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles BJ
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996 Jul; 48(1):47-57.
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies.
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol. 1996 May; 14(2 Suppl 2):12-20; discussion 21.
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.
Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, Martin SK, Oesterling JE
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol. 1994 Nov; 12(11):2254-63.
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution.
Kerr LA, Blute ML, Ryu JH, Swensen SJ, Malek RS
Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis? Urology. 1993 May; 41(5):440-4.
Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis?
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML
The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009 Jan; 181(1):95-104; discussion 104.
The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy.
Editorial comment. Urology. 2011 Apr; 77(4):950-1.
Umbreit EC, Shimko MS, Childs MA, Lohse CM, Cheville JC, Leibovich BC, Blute ML, Thompson RH
Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int. 2012 Jan; 109(2):190-4; discussion 194.
Metastatic potential of a renal mass according to original tumour size at presentation.
Guthman DA, Wilson TM, Blute ML, Bergstralh EJ, Zincke H, Oesterling JE
Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. Urology. 1993 Aug; 42(2):150-4.
Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.
Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011 May; 59(5):832-40.
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr Urol Rep. 2012 Feb; 13(1):38-46.
Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.
Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML, Charboneau JW
Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. 2008 Jun; 179(6):2136-40; discussion 2140-1.
Percutaneous renal cryoablation: experience treating 115 tumors.
Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise? J Clin Oncol. 2008 May 10; 26(14):2248-9.
Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise?
Ida CM, Wang X, Erickson-Johnson MR, Wenger DE, Blute ML, Nascimento AG, Oliveira AM
The American journal of surgical pathology
Primary retroperitoneal lipoma: a soft tissue pathology heresy?: report of a case with classic histologic, cytogenetics, and molecular genetic features. Am J Surg Pathol. 2008 Jun; 32(6):951-4.
Primary retroperitoneal lipoma: a soft tissue pathology heresy?: report of a case with classic histologic, cytogenetics, and molecular genetic features.
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 01; 68(15):6054-8.
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.
Bruner B, Breau RH, Lohse CM, Leibovich BC, Blute ML
Renal nephrometry score is associated with urine leak after partial nephrectomy. BJU Int. 2011 Jul; 108(1):67-72.
Renal nephrometry score is associated with urine leak after partial nephrectomy.
Blute ML, Okhunov Z, Moreira DM, George AK, Sunday S, Lobko II, Vira MA
Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int. 2013 Apr; 111(4 Pt B):E181-5.
Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications.
Angiomyolipoma: clinical metamorphosis and concepts for management. J Urol. 1988 Jan; 139(1):20-4.
Angiomyolipoma: clinical metamorphosis and concepts for management.
Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994 Nov; 152(5 Pt 2):1850-7.
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
Torres VE, King BF, Holley KE, Blute ML, Gomez MR
Advances in nephrology from the Necker Hospital
The kidney in the tuberous sclerosis complex. Adv Nephrol Necker Hosp. 1994; 23:43-70.
The kidney in the tuberous sclerosis complex.
Elliott DS, Blute ML, Patterson DE, Bergstralh EJ, Segura JW
Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996 Jun; 47(6):819-25.
Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.
Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004 Apr; 28(4):435-41.
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy. Urology. 2004 Aug; 64(2):376-7.
Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy.
Nephron-sparing surgery: the 'gold standard' treatment for small renal cortical tumors. Nat Clin Pract Urol. 2007 Jun; 4(6):300-1.
Nephron-sparing surgery: the 'gold standard' treatment for small renal cortical tumors.
Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007 May; 16(5):969-78.
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol. 2008 Oct; 54(4):855-63.
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.
Continent orthotopic urinary diversion in female patients: early Mayo Clinic experience. Mayo Clin Proc. 1998 Jun; 73(6):501-7.
Continent orthotopic urinary diversion in female patients: early Mayo Clinic experience.
Current status of transurethral thermotherapy at the Mayo Clinic. Mayo Clin Proc. 1998 Jun; 73(6):597-602.
Current status of transurethral thermotherapy at the Mayo Clinic.
Granberg CF, Boorjian SA, Crispen PL, Tollefson MK, Farmer SA, Frank I, Blute ML
Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int. 2008 Dec; 102(11):1551-5.
Functional and oncological outcomes after orthotopic neobladder reconstruction in women.
Tollefson MK, Krambeck AE, Leibovich BC, Blute ML, Chow GK
Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology. 2010 Jun; 75(6):1373-7.
Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient.
Editorial comment. Urology. 2009 Nov; 74(5):1046; author reply 1046-7.
Editorial comment. J Urol. 2010 Apr; 183(4):1365.
Unilateral renal cortical necrosis. Br J Urol. 1985 Apr; 57(2):243-4.
Refining the early detection and staging of prostate cancer. J Urol. 1995 Oct; 154(4):1401-2.
Refining the early detection and staging of prostate cancer.
Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol. 1995 Oct; 154(4):1447-52.
Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity.
Endourologic diagnosis and conservative management of upper tract urothelial cancer. Urol Nurs. 1994 Dec; 14(4):159-63.
Endourologic diagnosis and conservative management of upper tract urothelial cancer.
Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology. 2000 Nov 01; 56(5):726-9.
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol. 1995 Sep; 154(3):1103-9.
Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
Medical management of overactive bladder. Mayo Clin Proc. 2001 Apr; 76(4):353-5.
Medical management of overactive bladder.
Blute ML, Itano NB, Cheville JC, Weaver AL, Lohse CM, Zincke H
The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol. 2003 Apr; 169(4):1276-81.
The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, Zincke H
A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003 Dec; 170(6 Pt 1):2225-32.
A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma.
Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M
Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2005 Jul; 174(1):107-10; discussion 110-1.
Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer.
The management of superficial transitional cell carcinoma of the bladder. Urology. 2006 Mar; 67(3 Suppl 1):48-54; discussion 54-5.
The management of superficial transitional cell carcinoma of the bladder.
Sengupta S, Slezak JM, Blute ML, Leibovich BC, Sebo TJ, Myers RP, Cheville JC, Bergstralh EJ, Zincke H
Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006 Jun 15; 106(12):2630-5.
Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML
Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol. 2006 Sep; 176(3):1118-21.
Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1.
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA, Frank I, Inman B, Lohse CM, Cheville JC, Leibovich BC, Blute ML
The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. Urology. 2007 Dec; 70(6):1064-8.
The role of partial nephrectomy for the management of sporadic renal angiomyolipoma.
Thompson RH, Cheville JC, Leibovich BC, Blute ML
Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882. J Urol. 2008 Jul; 180(1):409; author reply 409-10.
Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882.
Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol. 2009 Dec; 182(6):2601-6.
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors.
Breau RH, Crispen PL, Jimenez RE, Lohse CM, Blute ML, Leibovich BC
Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol. 2010 Mar; 183(3):903-8.
Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy.
Surgery for renal cell carcinoma metastases. Curr Opin Urol. 2010 Sep; 20(5):375-81.
Surgery for renal cell carcinoma metastases.
Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011 Jul 01; 117(13):2873-82.
Survival after complete surgical resection of multiple metastases from renal cell carcinoma.
Lerner SE, Blute ML, Lieber MM, Zincke H
Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. Oncology (Williston Park). 1995 May; 9(5):379-82; discussion 382, 385-6, 389.
Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer.
Lerner SE, Hawkins CA, Blute ML, Grabner A, Wollan PC, Eickholt JT, Zincke H
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol. 1996 Jun; 155(6):1868-73.
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.
Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, Iczkowski K
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997 Sep 01; 80(5):987-9.
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998 Jun 01; 82(11):2256-61.
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Djavan B, Larson TR, Blute ML, Marberger M
Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? Urology. 1998 Dec; 52(6):935-47.
Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia?
Seelig MH, Oldenburg WA, Klingler PJ, Blute ML, Pairolero PC
Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. J Vasc Surg. 1999 Feb; 29(2):377-81.
Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report.
Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer. 2001 Jun 01; 91(11):2196-204.
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Local microwave hyperthermia as a treatment alternative for benign prostatic hyperplasia. J Androl. 1991 Nov-Dec; 12(6):429-34.
Local microwave hyperthermia as a treatment alternative for benign prostatic hyperplasia.
Chow GK, Patterson DE, Blute ML, Segura JW
Ureteroscopy: effect of technology and technique on clinical practice. J Urol. 2003 Jul; 170(1):99-102.
Ureteroscopy: effect of technology and technique on clinical practice.
Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, Zincke H
pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol. 2005 Feb; 173(2):380-4.
pT2 classification for renal cell carcinoma. Can its accuracy be improved?
Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML
Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol. 2005 Sep; 174(3):855-8.
Complications of contemporary open nephron sparing surgery: a single institution experience.
Humphreys MR, Ereth MH, Sebo TJ, Slezak JM, Dong Y, Blute ML, Gettman MT
Can the kidney function as a lung? Systemic oxygenation and renal preservation during retrograde perfusion of the ischaemic kidney in rabbits. BJU Int. 2006 Sep; 98(3):674-9.
Can the kidney function as a lung? Systemic oxygenation and renal preservation during retrograde perfusion of the ischaemic kidney in rabbits.
Surgical management of renal cell carcinoma. Semin Oncol. 2006 Oct; 33(5):552-62.
Surgical management of renal cell carcinoma.
Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1749-56.
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
Siddiqui SA, Boorjian SA, Blute ML, Rangel LJ, Bergstralh EJ, Karnes RJ, Frank I
Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int. 2011 Feb; 107(3):383-8.
Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS
Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol. 2019 04; 201(4):721-727.
Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years.
Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, Oesterling JE
Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology. 1993 Jan; 41(1):3-8.
Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.
Hanna N, Wszolek MF, Mojtahed A, Nicaise E, Wu B, Gelpi-Hammerschmidt FJ, Salari K, Dahl DM, Blute ML, Harisinghani M, Feldman AS
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer. J Urol. 2019 11; 202(5):944-951.
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer.
Jerome and Nancy Kohlberg Professor of Medicine
Management of Local Kidney Cancer Relapse. Eur Urol Oncol. 2018 12; 1(6):524.
Management of Local Kidney Cancer Relapse.
Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK
Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? Eur Urol Oncol. 2019 07; 2(4):365-378.
Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
Associate Professor of Surgery (Urology)
Elliott Carr Cutler Professor of Surgery
Wu S, Lin X, Lin SX, Lu M, Deng T, Wang Z, Olumi AF, Dahl DM, Wang D, Blute ML, Wu CL
Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis. Scand J Urol. 2019 Oct; 53(5):287-294.
Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis.
Revisiting the role of lymph node dissection in renal cell carcinoma. Ann Transl Med. 2019 Jul; 7(Suppl 3):S91.
Revisiting the role of lymph node dissection in renal cell carcinoma.
Wu S, Xie L, Lin SX, Wirth GJ, Lu M, Zhang Y, Blute ML, Dahl DM, Wu CL
Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence. Hum Pathol. 2020 10; 104:96-104.
Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence.
Zheng Y, Lin SX, Wu S, Dahl DM, Blute ML, Zhong WD, Zhou X, Wu CL
Clinicopathological characteristics of localized prostate cancer in younger men aged = 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta-analysis. Cancer Med. 2020 09; 9(18):6473-6484.
Clinicopathological characteristics of localized prostate cancer in younger men aged = 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta-analysis.
Wang Y, Liu Y, Deng W, Fu F, Yan S, Yang H, Liu R, Geng J, Xu J, Wu Y, Ma J, Zhou J, Liu N, Jin Y, Xia R, Elias N, Lee RJ, Feldman AS, Blute ML, Colvin RB, Wu CL, Miao Y
Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing. Oncogene. 2020 08; 39(35):5734-5742.
Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing.
Lin SX, Zheng Y, Wu S, Blute ML, Dahl DM, Wu CL
Impact of biopsy perineural invasion on younger prostate cancer patients after radical prostatectomy. Scand J Urol. 2020 Dec; 54(6):475-480.
Impact of biopsy perineural invasion on younger prostate cancer patients after radical prostatectomy.
Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Olumi AF, Dahl DM, Blute ML, Wu CL
Long-term Oncologic Impact of Positive Anterior and Posterior Surgical Margins After Radical Prostatectomy. Am J Clin Oncol. 2020 12 01; 43(12):872-879.
Long-term Oncologic Impact of Positive Anterior and Posterior Surgical Margins After Radical Prostatectomy.
Jin Y, Zhou Y, Deng W, Wang Y, Lee RJ, Liu Y, Elias N, Hu Y, Luo MH, Liu R, Guan B, Geng J, Xu J, Ma J, Zhou J, Liu N, Blute ML, Colvin RB, Wu CL, Miao Y
Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level. Oncogene. 2021 01; 40(1):46-54.
Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level.
Pieretti A, Krasnow R, Drumm M, Gusev A, Dahl DM, McGovern F, Blute ML, Shipley WU, Efstathiou JA, Feldman AS, Wszolek MF
Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. J Urol. 2021 Jul; 206(1):29-36.
Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
Yu A, Yamany T, Mojtahed A, Hanna N, Nicaise E, Harisinghani M, Wu CL, Dahl DM, Wszolek M, Blute ML, Feldman AS
Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification. Urol Oncol. 2022 02; 40(2):59.e1-59.e5.
Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification.
Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013. Asian J Urol. 2023 Jan; 10(1):9-18.
Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013.
Schneider AC, Chandrasekar T, Bowler N, Fogg R, Leong JY, Gusev A, Rodgers LH, McCormick SR, Dahl DM, Efstathiou JA, Blute ML, Zietman AL, Wu CL, Smith MR, Van Allen EM, Feldman AS, Salari K
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer. J Urol. 2023 06; 209(6):1112-1119.
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. Urol Clin North Am. 2023 May; 50(2):261-284.
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus.
The Progession Landscape of Diagnostic and Treatment Options for Kidney Cancer. Urol Clin North Am. 2023 05; 50(2):xv-xvi.
The Progession Landscape of Diagnostic and Treatment Options for Kidney Cancer.
Salari K, Kowitz J, Twum-Ampofo J, Gusev A, O'Shea A, Anderson MA, Harisinghani M, Kuppermann D, Dahl DM, Efstathiou JA, Lee RJ, Blute ML, Zietman AL, Feldman AS
Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer. Urol Oncol. 2023 09; 41(9):387.e9-387.e16.
Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer.
Wu S, Lin SX, Cornejo KM, Crotty RK, Blute ML, Dahl DM, Wu CL
Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis. Asian J Urol. 2023 Jul; 10(3):317-328.
Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis.
Nicaise E, Feldman AS, Gusev A, Yu A, Nimmagadda N, Wszolek MF, McGovern F, Blute ML, Dahl DM
A contemporary comparison of laparoscopic versus open partial nephrectomy for renal cell carcinoma. BMC Urol. 2024 Mar 12; 24(1):58.
A contemporary comparison of laparoscopic versus open partial nephrectomy for renal cell carcinoma.
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
Comprehensive molecular characterization of clear cell renal cell carcinoma.
Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy. Oncology (Williston Park). 2013 Jul; 27(7):647-55.
Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy.
Wang T, Languino LR, Lian J, Stein G, Blute M, Fitzgerald TJ
Molecular targets for radiation oncology in prostate cancer. Front Oncol. 2011; 1:17.
Molecular targets for radiation oncology in prostate cancer.
Racial Differences in Survival for Locally Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2025 Jun; 23(3):102327.
Racial Differences in Survival for Locally Advanced Renal Cell Carcinoma.
Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume. Ann Surg. 2014 Jan; 259(1):7-9.
Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume.
Positive surgical margins after radical prostatectomy: does it matter? Eur Urol. 2014 Feb; 65(2):314-5.
Positive surgical margins after radical prostatectomy: does it matter?
Gusev A, Rumpf F, Zlatev D, Twum-Ampofo JK, Gore JL, Dahl DM, Wszolek MF, Efstathiou J, Lee RJ, Blute ML, Salari K, Feldman AS
PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance. Urol Oncol. 2025 Dec; 43(12):709.e9-709.e17.
PSA density as a dynamic prognostic marker of biopsy grade progression during active surveillance.
Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA
International journal of radiation oncology, biology, physics
Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56.
Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.
Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD
Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):355-61.
Prognostic significance of indeterminate lung nodules in renal cell carcinoma.
The role of lymphadenectomy in the management of renal cell carcinoma. World J Urol. 2014 Jun; 32(3):643-9.
The role of lymphadenectomy in the management of renal cell carcinoma.
Cao Y, Kim J, Talluto J, McVeigh T, Blute ML, Dahl DM, Salari K, Heidari P, Esfahani SA
89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma. Pharmaceutics. 2026 Feb 19; 18(2).
89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma.
Karnes RJ, Joniau S, Blute ML, Van Poppel H
Caveat emptor. Eur Urol. 2014 Oct; 66(4):673-5; discussion 675-6.
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol. 2015 Jan; 25(1):83-8.
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.
Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J Clin Oncol. 2014 Dec 10; 32(35):3926-9.
Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer.
Damaschke NA, Yang B, Blute ML, Lin CP, Huang W, Jarrard DF
Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer. Neoplasia. 2014 Dec; 16(12):1018-27.
Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancer.
Emergency cardiopulmonary bypass for massive pulmonary embolism occurring during nephrectomy. A A Case Rep. 2015 May 01; 4(9):117-9.
Emergency cardiopulmonary bypass for massive pulmonary embolism occurring during nephrectomy.
Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H
Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015 Mar; 67(3):460-7.
Defining a standard set of patient-centered outcomes for men with localized prostate cancer.
Prince J, Bultman E, Hinshaw L, Drewry A, Blute M, Best S, Lee FT, Ziemlewicz T, Lubner M, Shi F, Nakada SY, Abel EJ
Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. J Urol. 2015 Jun; 193(6):1899-904.
Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings.
Volpe A, Blute ML, Ficarra V, Gill IS, Kutikov A, Porpiglia F, Rogers C, Touijer KA, Van Poppel H, Thompson RH
Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. Eur Urol. 2015 Jul; 68(1):61-74.
Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature.
Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF
Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015 Aug; 12(8):435-44.
Addressing the need for repeat prostate biopsy: new technology and approaches.
Preston MA, Feldman AS, Coen JJ, McDougal WS, Smith MR, Paly JJ, Carrasquillo R, Wu CL, Dahl DM, Barrisford GW, Blute ML, Zietman AI
Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. Urol Oncol. 2015 Sep; 33(9):383.e9-16.
Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.
Huang J, Feldman AS, Dong L, Cornejo K, Liu Q, Dahl DM, Wu S, Blute ML, Huang Y, Wu CL
Preoperative Anemia as an Independent Prognostic Indicator of Papillary Renal Cell Carcinoma. Clin Genitourin Cancer. 2015 Oct; 13(5):e353-60.
Preoperative Anemia as an Independent Prognostic Indicator of Papillary Renal Cell Carcinoma.
Percutaneous biopsy for risk stratification of renal masses. Ther Adv Urol. 2015 Oct; 7(5):265-74.
Percutaneous biopsy for risk stratification of renal masses.
Blute ML, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2015 Nov; 194(5):1214-9.
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
The evolving role of renal mass biopsy. Ann Transl Med. 2016 Feb; 4(4):83.
Blute ML, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 09; 118(3):399-407.
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer.
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
Grimes MD, Blute ML, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology. 2016 Oct; 96:93-98.
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery.
Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology. 2017 Feb; 100:139-144.
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis.
Granberg C, Thompson RH, Quevedo JF, Karnes RJ, Frank I, Kwon ED, Blute ML
Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy. J Clin Oncol. 2009 May 20; 27(15_suppl):e16103.
Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy.
Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA
Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017 07; 72(1):54-60.
Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD
Prognostic significance of indeterminate lung nodules in renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):377.
Lerner SE, Jacobsen SJ, Lilja H, Bergstralh EJ, Ransom J, Klee GG, Piironen T, Blute ML, Lieber MM, Zincke H, Pettersson K, Peterson D, Oesterling JE
Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology. 1996 Aug; 48(2):240-8.
Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.
Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H
Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys. 1996 Oct 01; 36(3):585-91.
Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens.
Lerner SE, Blute ML, Richardson RL, Zincke H
Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Mayo Clin Proc. 1996 Oct; 71(10):945-50.
Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract.
vander Kooy MJ, Pisansky TM, Cha SS, Blute ML
Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology. 1997 Jan; 49(1):65-70.
Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy.
Larson TR, Blute ML, Tri JL, Whitlock SV
Contrasting heating patterns and efficiency of the Prostatron and Targis microwave antennae for thermal treatment of benign prostatic hyperplasia. Urology. 1998 Jun; 51(6):908-15.
Contrasting heating patterns and efficiency of the Prostatron and Targis microwave antennae for thermal treatment of benign prostatic hyperplasia.
Nehra A, Blute ML, Barrett DM, Moreland RB
International journal of impotence research
Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002 Feb; 14 Suppl 1:S38-42.
Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy.
Quality-of-life assessment in patients treated with lower-energy thermotherapy: Prostasoft 2.0. World J Urol. 1998; 16(2):148-52.
Quality-of-life assessment in patients treated with lower-energy thermotherapy: Prostasoft 2.0.
O'Leary MP, Baum NH, Blizzard R, Blute ML, Cooper TP, Dineen MK, Fenninger RB, Gee WF, Gormley EA, Ignatoff JM, Nachtsheim DA, Painter MR, Thomas R, Wei JT
2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol. 2002 Aug; 168(2):649-52.
2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction.
Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG
Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001 Jan 01; 91(1):66-73.
Risk of prostate carcinoma death in patients with lymph node metastasis.
Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML
Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology. 2001 Aug; 58(2):174-8.
Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney.
Gettman MT, Blute ML, Peschel R, Bartsch G
Current status of robotics in urologic laparoscopy. Eur Urol. 2003 Feb; 43(2):106-12.
Current status of robotics in urologic laparoscopy.
Trock BJ, Brotzman M, Utz WJ, Ugarte RR, Kaplan SA, Larson TR, Blute ML, Roehrborn CG, Partin AW
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years. Urology. 2004 Apr; 63(4):716-21.
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.
Zincke H, Blute ML, Fallen MJ, Farrow GM
Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome. J Urol. 1991 Oct; 146(4):1053-8.
Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.
Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, Sebo TJ, Nehra A, Zincke H
Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer. 2004 Oct 15; 101(8):1803-8.
Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML
Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol. 2005 Feb; 173(2):391-4.
Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients.
A giant left renal cyst presenting as obesity: a unique presentation. Arch Esp Urol. 1998 Jan-Feb; 51(1):105-7.
A giant left renal cyst presenting as obesity: a unique presentation.
Cheng L, Neumann RM, Blute ML, Zincke H, Bostwick DG
Journal of the National Cancer Institute
Long-term follow-up of untreated stage T1a prostate cancer. J Natl Cancer Inst. 1998 Jul 15; 90(14):1105-7.
Long-term follow-up of untreated stage T1a prostate cancer.
Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Blute ML, Russo P, Kwon ED, Allison JP
Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma. J Clin Oncol. 2008 May 20; 26(15_suppl):5052.
Evaluation of soluble B7x as a serum marker in patients with clear cell renal cell carcinoma.
Blute ML, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF
A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol. 2017 May; 35(5):729-735.
A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
Sengupta S, Zincke H, Leibovich BC, Blute ML
Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series. BJU Int. 2005 Jul; 96(1):54-7.
Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series.
Blute ML, Abramson JS, Cronin KC, Nardi V
Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass. N Engl J Med. 2017 02 16; 376(7):684-692.
Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass.
Blute ML, Damaschke N, Wagner J, Yang B, Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W, Jarrard DF
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One. 2017; 12(2):e0172048.
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.
Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG
The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000 May; 6(5):1896-9.
The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.
Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006 Aug 01; 107(3):521-9.
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC
Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006 Nov; 176(5):1978-82; discussion 1982-3.
Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma.
Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN
Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet. 1998 Jun; 62(6):1425-38.
Evidence for autosomal dominant inheritance of prostate cancer.
Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Segura JW, Zincke H, Elliott DS, Blute ML
Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol. 2007 May; 177(5):1721-6.
Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma.
Siddiqui SA, Mynderse LA, Zincke H, Hoffmann NE, Lobo JR, Wilson TM, Kawashima A, Davis BJ, Blute ML
Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience. Urology. 2007 Jul; 70(1):80-5.
Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.
Editorial comment. Urology. 2009 Jul; 74(1):159; author reply 160.
Primary signet ring cell adenocarcinoma of the bladder. J Urol. 1989 Jan; 141(1):17-21.
Primary signet ring cell adenocarcinoma of the bladder.
Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML
Journal of the American College of Surgeons
Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life. J Am Coll Surg. 2010 Feb; 210(2):232-9.
Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life.
Surgical Treatment of 4-10?cm Renal-Cell Carcinoma: A Survey of the Lions and Gazelles. J Endourol. 2017 04; 31(S1):S43-S47.
Surgical Treatment of 4-10?cm Renal-Cell Carcinoma: A Survey of the Lions and Gazelles.
Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002 Jan; 167(1):117-22.
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Minimally invasive therapies for benign prostatic hyperplasia. Urology. 2001 Dec; 58(6 Suppl 1):33-40; discussion 40-1.
Minimally invasive therapies for benign prostatic hyperplasia.
Update on pathologic staging of renal cell carcinoma. Urology. 2002 Aug; 60(2):209-17.
Update on pathologic staging of renal cell carcinoma.
Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2002 Sep 01; 95(5):1028-36.
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Gettman MT, Boelter CW, Cheville JC, Zincke H, Bryant SC, Blute ML
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol. 2003 Apr; 169(4):1282-6.
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension.
Chemoprevention of prostate cancer. Expert Rev Anticancer Ther. 2003 Apr; 3(2):203-14.
Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol. 2003 Aug; 170(2 Pt 1):420-4.
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma.
DiMarco DS, Blute ML, Zincke H, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Sebo TJ
Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less. Urol Oncol. 2003 Nov-Dec; 21(6):439-46.
Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less.
Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H
A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004 Aug; 172(2):465-9.
A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.
Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8.
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG
Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology. 1998 Jan; 51(1):79-85.
Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis.
Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998 May; 159(5):1497-503.
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 1998 Feb; 159(2):357-64.
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.
Blute ML, Amling CL, Bryant SC, Zincke H
Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease. Mayo Clin Proc. 2000 Oct; 75(10):1020-6.
Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urology. 2001 Apr; 57(4 Suppl 1):188-90.
Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol. 2002 Dec; 118(6):877-86.
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients.
Nuttall GA, Cragun MD, Hill DL, Morris TJ, Decker PA, Blute ML, Patterson DE, Warner DO
Radical retropubic prostatectomy and blood transfusion. Mayo Clin Proc. 2002 Dec; 77(12):1301-5.
Radical retropubic prostatectomy and blood transfusion.
Farrell MA, Charboneau JW, Callstrom MR, Reading CC, Engen DE, Blute ML
Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2003 Nov; 181(5):1315-7.
Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation.
Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML
Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006 Feb; 175(2):547-51.
Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
Sengupta S, Slezak JM, Blute ML, Bergstralh EJ
Simple graphic method for estimation of prostate-specific antigen doubling time. Urology. 2006 Feb; 67(2):408-9.
Simple graphic method for estimation of prostate-specific antigen doubling time.
Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Zincke H, Blute ML
Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006 Sep; 176(3):900-3; discussion 903-4.
Second primary malignancies associated with renal cell carcinoma histological subtypes.
Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML
Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017 10; 198(4):810-816.
Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.
At what point does warm ischemia cause permanent renal damage during partial nephrectomy? Eur Urol. 2007 Oct; 52(4):961-3.
At what point does warm ischemia cause permanent renal damage during partial nephrectomy?
Harmon WJ, Sershon PD, Blute ML, Patterson DE, Segura JW
Ureteroscopy: current practice and long-term complications. J Urol. 1997 Jan; 157(1):28-32.
Ureteroscopy: current practice and long-term complications.
Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999 Mar; 161(3):857-62; discussion 862-3.
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Blute M, Ackerman SJ, Rein AL, Beusterien K, Sullivan EM, Tanio CP, Strauss MJ, Manyak MJ
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results. Urology. 2000 Dec 20; 56(6):981-7.
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results.
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996. J Urol. 2002 Feb; 167(2 Pt 2):884-9; discussion 889-90.
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996.
Lymph Node Dissection for Small Renal Masses. Urol Clin North Am. 2017 May; 44(2):269-274.
Lymph Node Dissection for Small Renal Masses.
Transurethral microwave thermotherapy: minimally invasive therapy for benign prostatic hyperplasia. Urology. 1997 Aug; 50(2):163-6.
Transurethral microwave thermotherapy: minimally invasive therapy for benign prostatic hyperplasia.
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Apr 01; 97(7):1663-71.
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem. 2004 Apr; 11(7):909-23.
The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer.
Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004 Jul; 94(1):33-41.
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus.
Blute ML, Jacobsen SJ, Kaplan SA, Lowe FC, O'Leary MP, Steers WD, Roehrborn CG
Introduction. Urology. 2001 Dec; 58(6 Suppl 1):1-4.
Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998 May; 73(5):401-6.
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001 Jan; 165(1):119-25.
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet. 2002 Jul; 71(1):116-23.
Analysis of the RNASEL gene in familial and sporadic prostate cancer.
Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Blute ML, Campbell SC
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol. 2010 Sep; 58(3):340-5.
Every minute counts when the renal hilum is clamped during partial nephrectomy.
Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1757-61.
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol. 2007 Aug; 178(2):459-63; discussion 463.
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ
Comparison of screening methods in the detection of bladder cancer. J Urol. 1999 Feb; 161(2):388-94.
Comparison of screening methods in the detection of bladder cancer.
Re: Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Oct; 162(4):1391-2.
Re: Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology.
O'Leary MP, Gee WF, Holtgrewe HL, Blute ML, Cooper TP, Meyer JJ, Miles BJ, Naslund MJ, Nellans RE, Thomas R, Painter MR, Blizzard R, Fenninger RB
1998 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of ureteral stones and impact of managed care. J Urol. 1999 Nov; 162(5):1702-4.
1998 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of ureteral stones and impact of managed care.
Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000 Mar; 163(3):845-50.
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000 Dec; 75(12):1236-42.
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney.
Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H
Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology. 2002 Apr; 59(4):532-7.
Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ, Zincke H
Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer. 2003 May 15; 97(10):2425-31.
Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome.
Cunningham JM, McDonnell SK, Marks A, Hebbring S, Anderson SA, Peterson BJ, Slager S, French A, Blute ML, Schaid DJ, Thibodeau SN
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Prostate. 2003 Dec 01; 57(4):335-46.
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.
Dimashkieh HH, Jevremovic D, Blute ML, Lager DJ
Pathologic quiz case: a 56-year-old man with bilateral renal masses. Bilateral renal oncocytosis. Arch Pathol Lab Med. 2004 Dec; 128(12):e177-8.
Pathologic quiz case: a 56-year-old man with bilateral renal masses. Bilateral renal oncocytosis.
Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006 Jul 01; 107(1):46-53.
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
Allaire PH, Messick JM, Oesterling JE, Byer DE, Myers RP, Lieber MM, Chantigian RC, Welna JO, Patterson DE, Blute ML
A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy. Mayo Clin Proc. 1992 Nov; 67(11):1031-41.
A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy.
Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Berry R, Schaid DJ, Smith JR, French AJ, Schroeder JJ, McDonnell SK, Peterson BJ, Wang ZY, Carpten JD, Roberts SG, Tester DJ, Blute ML, Trent JM, Thibodeau SN
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet. 2000 Feb; 66(2):539-46.
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer.
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000 Aug; 164(2):322-5.
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Kallman DA, King BF, Hattery RR, Charboneau JW, Ehman RL, Guthman DA, Blute ML
Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr. 1992 Mar-Apr; 16(2):240-7.
Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography.
Lau WK, Zincke H, Lohse CM, Cheville JC, Weaver AL, Blute ML
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int. 2003 Jun; 91(9):775-9.
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review.
Larson TR, Blute ML, Bruskewitz RC, Mayer RD, Ugarte RR, Utz WJ
A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial. Urology. 1998 May; 51(5):731-42.
A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial.
Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H
Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999 Apr; 161(4):1223-7; discussion 1227-8.
Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison.
Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer. 2002 Aug 01; 95(3):513-9.
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.
Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Parker AS, Lohse CM, Wu K, Kreinest P, Copland JA, Hilton T, Wehle M, Cheville JC, Blute M
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma. Hum Pathol. 2007 Mar; 38(3):453-61.
Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clear cell renal cell carcinoma.
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005 Nov 15; 104(10):2084-91.
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005 Nov; 174(5):1759-63; discussion 1763.
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001 Apr; 165(4):1146-51.
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
Tollefson MK, Boorjian SA, Lohse CM, Blute ML, Leibovich BC
The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma. BJU Int. 2010 Dec; 106(11):1638-42.
The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma.
Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol. 2001 Nov; 166(5):1692-7.
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Wang L, McDonnell SK, Cunningham JM, Hebbring S, Jacobsen SJ, Cerhan JR, Slager SL, Blute ML, Schaid DJ, Thibodeau SN
No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet. 2003 Oct; 35(2):128-9.
No association of germline alteration of MSR1 with prostate cancer risk.
Childs MA, Breau RH, Umbreit EC, Lohse CM, Cheville JC, Thompson RH, Blute ML, Leibovich BC
Metachronous renal tumours after surgical management of oncocytoma. BJU Int. 2011 Sep; 108(6):816-9.
Metachronous renal tumours after surgical management of oncocytoma.
Cheville JC, Zincke H, Lohse CM, Sebo TJ, Riehle D, Weaver AL, Blute ML
pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer. 2002 Apr 15; 94(8):2180-4.
pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003 Feb; 72(2):270-80.
Mutations in CHEK2 associated with prostate cancer risk.
Ureteroscopy. J Urol. 1988 Mar; 139(3):510-2.
Defining the appropriate patient population for primary brachytherapy for localized prostate cancer: work in progress. Mayo Clin Proc. 2004 Mar; 79(3):307-8.
Defining the appropriate patient population for primary brachytherapy for localized prostate cancer: work in progress.
Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6.
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ, Tran NV, Zincke H, Blute ML
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol. 2005 Jun; 173(6):1953-7.
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.
Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC
Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005 Jul 01; 104(1):53-60.
Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.
Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED
The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006 Jan 15; 106(2):304-12.
The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
Re: The accuracy of 250 fine needle biopsies of renal tumors. J Urol. 2005 Dec; 174(6):2422; author reply 2422.
Re: The accuracy of 250 fine needle biopsies of renal tumors.
Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, Leibovich BC
Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol. 2006 Jan; 175(1):53-6.
Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006 Jul 01; 107(1):37-45.
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
Siddiqui SA, Frank I, Leibovich BC, Cheville JC, Lohse CM, Zincke H, Blute ML
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol. 2007 Jan; 177(1):59-62.
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma.
Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, Zincke H
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997 Nov; 50(5):733-9.
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ
Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007 Aug; 178(2):440-5; discussion 444.
Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy.
Transvesical peritoneoscopy: initial clinical evaluation of the bladder as a portal for natural orifice translumenal endoscopic surgery. Mayo Clin Proc. 2007 Jul; 82(7):843-5.
Transvesical peritoneoscopy: initial clinical evaluation of the bladder as a portal for natural orifice translumenal endoscopic surgery.
Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008 Feb; 179(2):468-71; discussion 472-3.
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.
Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
Krambeck A, Iwaszko M, Leibovich B, Cheville J, Frank I, Blute M
Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery. BJU Int. 2008 Jun; 101(11):1375-9.
Long-term outcome of multiple ipsilateral renal tumours found at the time of planned nephron-sparing surgery.
Hakimian P, Blute M, Kashanian J, Chan S, Silver D, Shabsigh R
Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int. 2008 Dec; 102(11):1509-14.
Metabolic and cardiovascular effects of androgen deprivation therapy.
Lymph node dissection in the management of renal cell carcinoma. Urol Clin North Am. 2008 Nov; 35(4):673-8; viii.
Lymph node dissection in the management of renal cell carcinoma.
Webster WS, Thompson RH, Cheville JC, Lohse CM, Blute ML, Leibovich BC
Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma. Urology. 2007 Nov; 70(5):900-4; discussion 904.
Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma.
Thompson RH, Krambeck AE, Lohse CM, Elliott DS, Patterson DE, Blute ML
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008 Apr; 71(4):713-7.
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys.
Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67(16):7893-900.
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Granberg CF, Krambeck AE, Leibovich BC, Frank I, Lohse CM, Gettman MT, Blute ML, Chow GC
Potential underdetection of pT(3a) renal-cell carcinoma with laparoscopic morcellation. J Endourol. 2007 Oct; 21(10):1183-6.
Potential underdetection of pT(3a) renal-cell carcinoma with laparoscopic morcellation.
Routh JC, Bacon DR, Leibovich BC, Zincke H, Blute ML, Frank I
How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery. BJU Int. 2008 Aug; 102(3):301-4.
How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery.
Blute ML, Bostwick DG, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, Zincke H
Pathologic classification of prostate carcinoma: the impact of margin status. Cancer. 1998 Mar 01; 82(5):902-8.
Pathologic classification of prostate carcinoma: the impact of margin status.
Ashley RA, Inman BA, Routh JC, Mynderse LA, Gettman MT, Blute ML
Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol. 2008 May; 53(5):976-81.
Reassessing the diagnostic yield of saturation biopsy of the prostate.
Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, Therneau TM, Lieber MM
Archives of surgery (Chicago, Ill. : 1960)
Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg. 1990 Mar; 125(3):327-31.
Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis.
Granberg CF, Boorjian SA, Schaff HV, Orszulak TA, Leibovich BC, Lohse CM, Cheville JC, Blute ML
Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass. Urology. 2008 Jul; 72(1):148-52.
Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass.
Dechet CB, Bostwick DG, Blute ML, Bryant SC, Zincke H
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol. 1999 Jul; 162(1):40-2.
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma.
Blute ML, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 2017 09; 120(3):387-393.
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.
Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL
Stage pT1 conventional (clear cell) renal cell carcinmoa: pathological features associated with cancer specific survival. J Urol. 2001 Aug; 166(2):453-6.
Stage pT1 conventional (clear cell) renal cell carcinmoa: pathological features associated with cancer specific survival.
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol. 2001 Dec; 166(6):2208-15.
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May; 167(5):2001-6.
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15(6):2174-80.
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
Surgery for vena caval tumor extension in renal cancer. Curr Opin Urol. 2009 Sep; 19(5):473-7.
Surgery for vena caval tumor extension in renal cancer.
Parker AS, Cheville JC, Lohse CM, Igel T, Leibovich BC, Blute ML
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma. Urology. 2005 Jun; 65(6):1090-5.
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma.
Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Lynch JH, Regan JB, Sankey NE
Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J Urol. 1993 Nov; 150(5 Pt 2):1591-6.
Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study.
Gettman MT, Blute ML, Chow GK, Neururer R, Bartsch G, Peschel R
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology. 2004 Nov; 64(5):914-8.
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system.
Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, Thompson RH, Blute ML
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved? J Urol. 2005 Mar; 173(3):716-9.
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005 Jun; 173(6):1889-92.
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
Alberts SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther. 2006 Jul-Aug; 13(4):291-7.
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
Magera JS, Frank I, Lohse CM, Leibovich BC, Cheville JC, Blute ML
Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant. J Urol. 2008 Mar; 179(3):853-6.
Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant.
Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol. 2008 Jul; 180(1):99-103; discussion 103.
Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy.
No proof of inferiority: open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer. J Urol. 2009 Jun; 181(6):2421-3.
No proof of inferiority: open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer.
Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol. 1996 Jul; 156(1):137-43.
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
Sengupta S, Blute ML, Bagniewski SM, Myers RP, Bergstralh EJ, Leibovich BC, Zincke H
Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol. 2006 May; 175(5):1684-90; discussion 1690.
Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ
The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105(10):1381-5.
The effect of Gleason score on the predictive value of prostate-specific antigen doubling time.
Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H
Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer. 2001 Jan 15; 91(2):354-61.
Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system.
Editorial comment. Urology. 2010 Sep; 76(3):721-2; discussion 722.
Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC, Blute ML
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol. 2011 Jan; 59(1):18-23.
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.
Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Campbell SC, Blute ML
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol. 2010 Sep; 58(3):331-6.
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney.
Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I
Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010 Sep; 184(3):925-9.
Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney. Urology. 2012 Feb; 79(2):356-60.
Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney.
Hillelsohn JH, Duty B, Blute ML, Okhunov Z, Kashan M, Moldwin R, Ashley RN
Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures. Can J Urol. 2012 Dec; 19(6):6573-7.
Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures.
Delayed Intervention of Small Renal Masses on Active Surveillance. J Kidney Cancer VHL. 2017; 4(2):24-30.
Delayed Intervention of Small Renal Masses on Active Surveillance.
Damaschke NA, Yang B, Bhusari S, Avilla M, Zhong W, Blute ML, Huang W, Jarrard DF
Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth. Cancer Res. 2017 10 01; 77(19):5236-5247.
Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010 Mar; 183(3):1003-9.
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.
Schmit GD, Atwell TD, Callstrom MR, Farrell MA, Leibovich BC, Patterson DE, Chow GK, Blute ML, Charboneau JW
Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients. J Endourol. 2010 Aug; 24(8):1255-62.
Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients.
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 01; 117(13):2883-91.
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H
Lymph node dissection in renal cell carcinoma. Eur Urol. 2011 Dec; 60(6):1212-20.
Lymph node dissection in renal cell carcinoma.
Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, Myers RP, Zincke H
Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol. 1997 Nov; 15(4):215-21.
Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate.
Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000 Nov; 164(5):1591-5.
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
Blute M, Thibault GP, Leibovich BC, Cheville JC, Lohse CM, Zincke H
Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence. J Urol. 2003 Sep; 170(3):760-3.
Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence.
Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol. 2004 Jan-Feb; 22(1):40-7.
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
Leung N, Ytterberg SR, Blute ML, Lager DJ, Specks U, Fervenza FC
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Wegener's granulomatosis presenting as multiple bilateral renal masses. Nephrol Dial Transplant. 2004 Apr; 19(4):984-7.
Wegener's granulomatosis presenting as multiple bilateral renal masses.
Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS
The use of urine-based biomarkers in bladder cancer. Urology. 2006 Mar; 67(3 Suppl 1):62-4.
The use of urine-based biomarkers in bladder cancer.
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 01; 66(7):3381-5.
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED
Proceedings of the National Academy of Sciences of the United States of America
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006 Jul 05; 103(27):10391-10396.
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.
Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006 Aug 15; 107(4):712-20.
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors </=4 cm. Adv Urol. 2008; 518091.
Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors </=4 cm.
Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, Leibovich BC
Outcomes following partial nephrectomy by tumor size. J Urol. 2008 Nov; 180(5):1912-7.
Outcomes following partial nephrectomy by tumor size.
Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R
Erectile dysfunction and testosterone deficiency. Front Horm Res. 2009; 37:108-122.
Erectile dysfunction and testosterone deficiency.
Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol. 2009 May; 55(5):1161-2.
Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization.
Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010 Apr; 183(4):1309-15.
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ
Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology. 2011 May; 77(5):1161-5.
Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy.
Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998 Oct; 20(2):175-9.
Evidence for a prostate cancer susceptibility locus on the X chromosome.
Blute ML, Tsushima K, Farrow GM, Therneau TM, Lieber MM
Transitional cell carcinoma of the renal pelvis: nuclear deoxyribonucleic acid ploidy studied by flow cytometry. J Urol. 1988 Nov; 140(5):944-9.
Transitional cell carcinoma of the renal pelvis: nuclear deoxyribonucleic acid ploidy studied by flow cytometry.
Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H
The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol. 2002 Jul; 168(1):56-60.
The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ
Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer. 2001 Jun 15; 91(12):2302-14.
Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis.
de la Rosette JJ, Blute ML, Desgrandchamp F
Transurethral thermotherapy using the Prostatron device. World J Urol. 1998; 16(2):89-95.
Transurethral thermotherapy using the Prostatron device.
Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology. 2003 Oct; 62(4):641-6.
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney. Urology. 2005 Oct; 66(4):882.
In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney.
Sengupta S, Cheville JC, Lohse CM, Zincke H, Myers RP, Riehle DL, Pankratz VS, Blute ML, Sebo TJ
Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. Urology. 2006 Jul; 68(1):94-8.
Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
Thompson RH, Blute ML, Krambeck AE, Lohse CM, Magera JS, Leibovich BC, Kwon ED, Frank I, Cheville JC
Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol. 2007 Jul; 31(7):1089-93.
Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion.
Jacobsen SJ, Thibodeau SN, McDonnell SK, Peterson BJ, Bergstralh EJ, Schaid DJ, Blute ML
Lack of referral bias in genetic studies of prostate cancer. Epidemiology. 2002 Sep; 13(5):612-3.
Lack of referral bias in genetic studies of prostate cancer.
Kausik SJ, Blute ML, Sebo TJ, Leibovich BC, Bergstralh EJ, Slezak J, Zincke H
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002 Sep 15; 95(6):1215-9.
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003 Dec; 170(6 Pt 1):2217-20.
Solid renal tumors: an analysis of pathological features related to tumor size.
Brown DR, Hofer RE, Patterson DE, Fronapfel PJ, Maxson PM, Narr BJ, Eisenach JH, Blute ML, Schroeder DR, Warner DO
Intrathecal anesthesia and recovery from radical prostatectomy: a prospective, randomized, controlled trial. Anesthesiology. 2004 Apr; 100(4):926-34.
Intrathecal anesthesia and recovery from radical prostatectomy: a prospective, randomized, controlled trial.
Cheville JC, Frank I, Leibovich BC, Lohse CM, Blute ML
Re: Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol. 2004 Sep; 172(3):1196; author reply 1196.
Re: Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology.
Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005 Aug 01; 104(3):511-20.
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
Renal cell carcinoma: vena caval involvement. BJU Int. 2007 May; 99(5 Pt B):1239-44.
Renal cell carcinoma: vena caval involvement.
Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2008 May; 179(5 Suppl):S7-S11.
Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009 Feb; 55(2):307-9.
Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies?
Siddiqui SA, Frank I, Cheville JC, Lohse CM, Leibovich BC, Blute ML
Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 2009 Sep; 104(6):778-85.
Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol.
Breau RH, Cheville JC, Lohse CM, Kwon ED, Blute ML
Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564. J Urol. 2009 Dec; 182(6):2979-80; author reply 2980-1.
Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564.
Ashley RA, Inman BA, Routh JC, Krambeck AE, Siddiqui SA, Mynderse LA, Gettman MT, Blute ML
Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. Cancer. 2007 Oct 15; 110(8):1708-14.
Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
Nehra A, Kumar R, Ramakumar S, Myers RP, Blute ML, McKusick MA
Pharmacoangiographic evidence of the presence and anatomical dominance of accessory pudendal artery(s). J Urol. 2008 Jun; 179(6):2317-20.
Pharmacoangiographic evidence of the presence and anatomical dominance of accessory pudendal artery(s).
Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011 Mar; 107(5):724-728.
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?
Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma? Can Urol Assoc J. 2010 Oct; 4(5):E137-40.
Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma?
Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59(6):893-9.
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
American journal of respiratory and critical care medicine
How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med. 1996 Nov; 154(5):1580-1.
How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?
Hanash KA, Aquilina JW, Barrett DM, Blute ML, Cockett AT, Corica FA, Hillman GG, Zbar B, Zhuang Z
Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs--Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997 Sep 01; 80(5):999-1001.
Clinical research priorities in renal cell carcinoma: renal cell carcinoma chemoprevention strategies including target populations, proposed agents, and clinical trial designs--Workgroup No. 6. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
Schaid DJ, Guenther JC, Christensen GB, Hebbring S, Rosenow C, Hilker CA, McDonnell SK, Cunningham JM, Slager SL, Blute ML, Thibodeau SN
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet. 2004 Dec; 75(6):948-65.
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci.
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004 Dec 07; 101(49):17174-9.
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Wegener's granulomatosis presenting as renal mass: a case for nephron-sparing surgery. Urology. 2005 Apr; 65(4):798.
Wegener's granulomatosis presenting as renal mass: a case for nephron-sparing surgery.
Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G
Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005 Jul 15; 11(14):5128-39.
Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.
Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005 Dec; 174(6):2191-6.
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML
The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol. 2006 Nov; 176(5):1990-5; discussion 1995.
The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML
Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006 Oct; 68(4):741-6.
Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.
Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG
Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999 Oct; 5(10):2820-3.
Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
O'Leary MP, Gee WF, Holtgrewe HL, Blute ML, Cooper TP, Miles BJ, Nellans RE, Thomas R, Painter MR, Meyer JJ, Naslund MJ, Gormley EA, Blizzard R, Fenninger RB
1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol. 2000 Oct; 164(4):1311-6.
1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care.
Sengupta S, Amling C, D'Amico AV, Blute ML
Prostate specific antigen kinetics in the management of prostate cancer. J Urol. 2008 Mar; 179(3):821-6.
Prostate specific antigen kinetics in the management of prostate cancer.
Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008 May; 179(5):1830-7; discussion 1837.
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Parker A, Lohse C, Cheville J, Leibovich B, Igel T, Blute M
International journal of urology : official journal of the Japanese Urological Association
Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma. Int J Urol. 2008 Apr; 15(4):304-8.
Evaluation of the association of current cigarette smoking and outcome for patients with clear cell renal cell carcinoma.
Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L
Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol. 2002 Sep; 168(3):1204-11.
Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Dechet CB, Zincke H, Sebo TJ, King BF, LeRoy AJ, Farrow GM, Blute ML
Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol. 2003 Jan; 169(1):71-4.
Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults.
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003 May; 27(5):612-24.
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.
Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM, Cerhan JR
Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer. 2004 Jun 15; 100(12):2577-82.
Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival.
Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy.
Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011 Aug; 60(2):205-10.
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM
Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol. 1989 Nov; 142(5):1262-5.
Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy.
Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ
Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int. 2011 Dec; 108(11):1762-8.
Dynamic prediction of metastases after radical prostatectomy for prostate cancer.
Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol. 2005 Oct; 174(4 Pt 1):1218-21.
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, Sengupta S, Kwon ED, Blute ML
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology. 2005 Nov; 66(5 Suppl):10-4.
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, Blute ML
Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008 Feb; 71(2):278-82.
Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008 Aug 15; 14(16):5150-7.
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
Surgical management of high risk prostate cancer: the Mayo Clinic experience. Urol Oncol. 2008 Sep-Oct; 26(5):530-2.
Surgical management of high risk prostate cancer: the Mayo Clinic experience.
Bruner B, Ashley R, Leibovich B, Blute M, LeRoy A
Case report: percutaneous catheter management of persistent urine leak due to iatrogenic infundibular stenosis after partial nephrectomy. J Endourol. 2009 Jan; 23(1):37-41.
Case report: percutaneous catheter management of persistent urine leak due to iatrogenic infundibular stenosis after partial nephrectomy.
Hoffmann NE, Gillett MD, Cheville JC, Lohse CM, Leibovich BC, Blute ML
Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol. 2008 Feb; 179(2):474-7.
Differences in organ system of distant metastasis by renal cell carcinoma subtype.
Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr; 179(4):1354-60; discussion 1360-1.
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
Umbreit EC, Crispen PL, Shimko MS, Farmer SA, Blute ML, Frank I
Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer. 2010 Jul 15; 116(14):3399-407.
Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma.
Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I
Long-term complications of conduit urinary diversion. J Urol. 2011 Feb; 185(2):562-7.
Long-term complications of conduit urinary diversion.
An interview with Michael Blute, MD. Interviewed by John Fitzpatrick. BJU Int. 2011 Nov; 108(9):1369-70.
An interview with Michael Blute, MD. Interviewed by John Fitzpatrick.
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG
Guideline for management of the clinical T1 renal mass. J Urol. 2009 Oct; 182(4):1271-9.
Guideline for management of the clinical T1 renal mass.
Editorial comment. Urology. 2011 Sep; 78(3):619; author reply 619.
Blute ML, George A, Herati A, Srinivasian A, Vira MA, Kavoussi LR, Richstone L
Intracorporeal neobladder reconstruction: pressure-flow urodyamic studies in cadaveric orthotopic neobladders. BJU Int. 2012 Feb; 109(3):434-6.
Intracorporeal neobladder reconstruction: pressure-flow urodyamic studies in cadaveric orthotopic neobladders.
Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008 Jun; 5(6):329-39.
Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus.
Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. BJU Int. 2008 Nov; 102(9):1107-10.
Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract.
Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Myers RP, Blute ML, Gettman MT
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int. 2009 Feb; 103(4):448-53.
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.
Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010 Jan; 57(1):110-1.
Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009 Dec; 182(6):2708-14.
Radiation therapy after radical prostatectomy: impact on metastasis and survival.
Atwell TD, Callstrom MR, Farrell MA, Schmit GD, Woodrum DA, Leibovich BC, Chow GK, Patterson DE, Blute ML, Charboneau JW
Percutaneous renal cryoablation: local control at mean 26 months of followup. J Urol. 2010 Oct; 184(4):1291-5.
Percutaneous renal cryoablation: local control at mean 26 months of followup.
Gee WF, Holtgrewe HL, Blute ML, Miles BJ, Naslund MJ, Nellans RE, O'Leary MP, Thomas R, Painter MR, Meyer JJ, Rohner TJ, Cooper TP, Blizzard R, Fenninger RB, Emmons L
1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol. 1998 Nov; 160(5):1804-7.
1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997.
Corica FA, Iczkowski KA, Cheng L, Zincke H, Blute ML, Wendel A, Sebo TJ, Neumann R, Bostwick DG
Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. J Urol. 1999 Feb; 161(2):408-11.
Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup.
Re: Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the Search database. J Urol. 2004 Feb; 171(2 Pt 1):808; author reply 808-9.
Re: Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the Search database.
Gillett MD, Gettman MT, Zincke H, Blute ML
Tissue ablation technologies for localized prostate cancer. Mayo Clin Proc. 2004 Dec; 79(12):1547-55.
Tissue ablation technologies for localized prostate cancer.
Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005 Apr; 173(4):1156-60.
Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.
Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications. J Urol. 1998 Sep; 160(3 Pt 1):721-3.
Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications.
Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML, Bostwick DG
Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998 Dec; 22(12):1491-500.
Cancer volume of lymph node metastasis predicts progression in prostate cancer.
Sengupta S, Leibovich BC, Blute ML, Zincke H
Surgery for metastatic renal cell cancer. World J Urol. 2005 Jul; 23(3):155-60.
Surgery for metastatic renal cell cancer.
Blute ML, Tomera KM, Hellerstein DK, Atkinson EJ, Patterson DE, Segura JW
Transurethral microwave thermotherapy for prostatism: early Mayo Foundation experience. Mayo Clin Proc. 1992 May; 67(5):417-21.
Transurethral microwave thermotherapy for prostatism: early Mayo Foundation experience.
Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H
Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000 Apr; 163(4):1178-82.
Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol. 2002 Apr; 26(4):431-9.
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.